Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258804 | 0.84 | ALDH1A1 (0.51) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL14364184 | 0.83 | ALDH1A1 (0.39) | ALDH1A1CYP2D6KDM4E | |
| SCHEMBL12870586 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8193648 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL13620545 | 0.82 | ALDH1A1 (0.40) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL17683026 | 0.81 | CYP2D6 (0.43) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8434176 | 0.81 | CYP2D6 (0.62) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8253488 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL12869546 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL15461521 | 0.80 | ALDH1A1 (0.38) | ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| US-7405194-B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | PRAECIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7348307-B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-25 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | ALDH1A1 1155/4885CYP2D6 2134/4885KDM4E 1216/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ALDH1A1 1683/4885CYP2D6 1363/4885KDM4E 3361/4885 |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | ALDH1A1 2278/4885CYP2D6 2876/4885KDM4E 1741/4885 |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | ALDH1A1 1155/4885CYP2D6 2134/4885KDM4E 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.